Yükleniyor... / Loading...
A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD
Bu çalışma, C9orf72 geninde tekrar genişlemesi bulunan ALS (amyotrophic lateral sclerosis) ve/veya FTD (frontotemporal dementia) olan hastalarda TPN-101 ilacını plasebo ile karşılaştırarak incelemektedir. Genetik testle C9orf72 hexanükleotid tekrar genişlemesi doğrulanmış ve belirli tanı ölçütlerini karşılayan hastalar katılabilmektedir. Çalışma Faz 2 aşamasında yürütülmüş ve tamamlanmıştır.
Yukarıdaki özet, resmî kaydın sade dile aktarılmış halidir. Orijinal İngilizce başlık referans için gösterilir.
Kriterler ClinicalTrials.gov kaydından orijinal İngilizce haliyle alınmıştır. Uygunluk kararını yalnızca deneyi yürüten ekip verebilir.
Inclusion Criteria: * Documentation of a clinical genetic test demonstrating a hexanucleotide repeat expansion (HRE) in the C9orf72 gene * Has a reliable caregiver/informant to accompany the patient to all study visits For patients with ALS (with or without FTD): * Diagnosis of ALS (probable, possible, laboratory-supported probable or definite) according to the World Federation of Neurology revised E1 Escorial criteria * Onset of weakness within 3 years prior to Screening * Slow vital capacity (SVC) ≥ 60% of predicted normal adjusted for sex, age, and height (from the sitting position) * Able to perform reproducible pulmonary function tests. * ALS Functional Rating Scale-Revised (ALSFRS-R) ≥ 30 and score of 3 or 4 on Item #3 (swallowing) at Screening For patients with FTD: * A gradual, progressive decline in behavior, language, or motor function consistent with mild cognitive impairment, mild behavioral impairment, mild cognitive/behavioral impairment, behavioral variant FTD, primary progressive aphasia, or amnestic syndrome * CDR Dementia Staging Instrument plus National Alzheimer's Coordinating Center Behavior and Language Domains (CDR plus NACC FTLD) global score of 0.5-2.0 at Screening Exclusion Criteria: * Presence of other significant neurological or psychiatric disorders * History of clinically significant brain abnormality * Clinically significant medical illness * Tracheostomy or diaphragmatic pacing * Autoimmune disease requiring treatment or management (quiescent rheumatoid arthritis, psoriasis, or controlled Type 1 diabetes are acceptable) * History of human immunodeficiency virus (HIV) or hepatitis B infection, or any active infection during Screening, unless the patient will have been symptom-free for at least 30 days prior to randomization